Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Issues Earnings Results

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) released its quarterly earnings data on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, FiscalAI reports.

Oaktree Acquisition Corp. III Life Sciences Trading Up 0.2%

OACC traded up $0.02 on Wednesday, hitting $10.76. The company had a trading volume of 141 shares, compared to its average volume of 41,066. The business’s fifty day simple moving average is $10.71 and its 200 day simple moving average is $10.68. Oaktree Acquisition Corp. III Life Sciences has a 12-month low of $10.30 and a 12-month high of $10.88.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Oaktree Acquisition Corp. III Life Sciences presently has a consensus rating of “Sell”.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Institutional investors have recently added to or reduced their stakes in the company. Rangeley Capital LLC boosted its position in Oaktree Acquisition Corp. III Life Sciences by 52.8% in the 1st quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after buying an additional 21,156 shares during the period. DLD Asset Management LP increased its holdings in Oaktree Acquisition Corp. III Life Sciences by 0.9% during the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after purchasing an additional 1,200 shares during the period. Lineage Point Capital LP purchased a new position in Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth $2,461,000. Empyrean Capital Partners LP raised its position in Oaktree Acquisition Corp. III Life Sciences by 20.0% during the 4th quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock valued at $9,522,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Radcliffe Capital Management L.P. raised its position in Oaktree Acquisition Corp. III Life Sciences by 67.1% during the 4th quarter. Radcliffe Capital Management L.P. now owns 377,065 shares of the company’s stock valued at $3,989,000 after purchasing an additional 151,403 shares in the last quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.